Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + TACE + lenvatinib + sintilimab for unresectable HCC with type III PVTT
ChiCTR2300072570Phase 2Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and sintilimab in hepatocellular carcinoma (HCC), sponsored by Fujian Provincial Hospital. Primary endpoint: overall survival. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
lenvatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300072570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072570.